Toronto Dominion Bank Buys New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Toronto Dominion Bank bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 34,300 shares of the company’s stock, valued at approximately $364,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank acquired a new position in Neumora Therapeutics during the fourth quarter valued at $1,168,000. Schonfeld Strategic Advisors LLC lifted its position in Neumora Therapeutics by 273.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company’s stock valued at $5,523,000 after purchasing an additional 381,676 shares during the period. Capital International Investors lifted its position in Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the period. Wells Fargo & Company MN increased its holdings in Neumora Therapeutics by 23.0% in the fourth quarter. Wells Fargo & Company MN now owns 70,653 shares of the company’s stock valued at $749,000 after buying an additional 13,196 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Neumora Therapeutics in the fourth quarter valued at $143,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Down 5.3%

NMRA opened at $0.68 on Friday. The firm has a market capitalization of $109.94 million, a PE ratio of -0.36 and a beta of 2.96. Neumora Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $17.19. The firm’s 50-day moving average price is $0.79 and its 200 day moving average price is $3.91.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). As a group, analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

NMRA has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. William Blair cut shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $6.00 to $2.00 in a report on Friday, March 7th. Finally, HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.29.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.